Detalhe da pesquisa
1.
Interventions and outcomes of patients with multiple myeloma receiving salvage therapy after BCMA-directed CAR T therapy.
Blood;
141(7): 756-765, 2023 02 16.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36327160
2.
Multi-Omics Profiling of the Tumor Microenvironment.
Adv Exp Med Biol;
1361: 283-326, 2022.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35230695
3.
Iberdomide increases innate and adaptive immune cell subsets in the bone marrow of patients with relapsed/refractory multiple myeloma.
Cell Rep Med;
: 101584, 2024 May 17.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38776911
4.
Pharmacodynamic changes in tumor and immune cells drive iberdomide's clinical mechanisms of activity in relapsed and refractory multiple myeloma.
Cell Rep Med;
: 101571, 2024 May 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-38776914
5.
Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed/refractory myeloma.
Blood Adv;
7(6): 1056-1064, 2023 03 28.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36018226
6.
Cellular mechanisms associated with sub-optimal immune responses to SARS-CoV-2 bivalent booster vaccination in patients with Multiple Myeloma.
EBioMedicine;
98: 104886, 2023 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-37995467
7.
CD8+ T cells: An ineffective armor against prolonged COVID-19 in cancer patients.
Cell Rep Med;
3(7): 100695, 2022 07 19.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35835105
8.
Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy.
Nat Med;
27(12): 2099-2103, 2021 12.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34893771
9.
Immunomodulation in Pomalidomide, Dexamethasone, and Daratumumab-Treated Patients with Relapsed/Refractory Multiple Myeloma.
Clin Cancer Res;
26(22): 5895-5902, 2020 11 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32928795
10.
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward.
medRxiv;
2020 Jun 29.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32577702
11.
A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward.
J Hematol Oncol;
13(1): 94, 2020 07 14.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32664919
12.
An inflammatory cytokine signature predicts COVID-19 severity and survival.
Nat Med;
26(10): 1636-1643, 2020 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32839624
13.
An inflammatory cytokine signature helps predict COVID-19 severity and death.
medRxiv;
2020 May 30.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32511562
14.
A phase II study of pomalidomide, daily oral cyclophosphamide, and dexamethasone in relapsed/refractory multiple myeloma.
Leuk Lymphoma;
61(9): 2208-2215, 2020 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-32812822
15.
Significance of prolonged QTc in acute exacerbations of COPD requiring hospitalization.
Int J Chron Obstruct Pulmon Dis;
13: 1937-1947, 2018.
Artigo
em Inglês
| MEDLINE
| ID: mdl-29942126
16.
Characteristics of measurable residual disease assessment in myeloma: a review of clinical trials from 2015-2020.
Blood Cancer J;
12(11): 155, 2022 11 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36379917
17.
A survey on the patient perspective on cure in multiple myeloma.
Lancet Haematol;
9(10): e716-e719, 2022 10.
Artigo
em Inglês
| MEDLINE
| ID: mdl-36174636
18.
Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients.
Cancer Cell;
40(5): 441-443, 2022 05 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-35390296
19.
Variable cellular responses to SARS-CoV-2 in fully vaccinated patients with multiple myeloma.
Cancer Cell;
39(11): 1442-1444, 2021 11 08.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34706273
20.
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma.
Cancer Cell;
39(8): 1028-1030, 2021 08 09.
Artigo
em Inglês
| MEDLINE
| ID: mdl-34242572